Work

Secukinumab induced Behçet’s syndrome: a report of two cases

Year: 2019

Type: article

Abstract: Secukinumab is a human monoclonal antibody against IL-17A that has been shown to be effective in psoriasis, psoriatic arthritis and ankylosing spondylitis (AS). On the other hand, in randomized controlled trials among patients with Crohn’s disease (CD) and uveitis due to Behçet’s syndrome (BS) treated with secukinumab, primary end points were not met and the drug caused more exacerbations compared to placebo. The drug fact sheet states that secukinumab should be used with caution in patients with CD; however, there are no warnings for those with BS. Here, we present two patients with AS treated with secukinumab; we observed exacerbation of BS in one and emergence of de novo BS in another. Although IL-17A is thought to contribute to the pathogenesis of BS, our observations suggest that it might have a protective role. Finally, we suggest caution is required with the inhibition of IL-17 in BS.

Source: Oxford Medical Case Reports

DOI: 10.1093/omcr/omz041

Authors: Elif Dincses, Berna Yurttas, Sinem N Esatoglu, Melike Melikoglu, Vedat Hamuryudan, Emire Seyahi

Institutions: Istanbul University-Cerrahpaşa, Istanbul University

Language: English

Topic: Ocular Diseases and Behçet’s Syndrome

Subfield: Ophthalmology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $1,103